Show simple item record

dc.contributor.authorBonovas, Stefanosen
dc.contributor.authorNikolopoulos, Georgios K.en
dc.contributor.authorBagos, Pantelis G.en
dc.creatorBonovas, Stefanosen
dc.creatorNikolopoulos, Georgios K.en
dc.creatorBagos, Pantelis G.en
dc.date.accessioned2018-06-22T09:52:37Z
dc.date.available2018-06-22T09:52:37Z
dc.date.issued2013
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/41434
dc.description.abstractAim: A growing body of evidence suggests that bisphosphonates may have chemopreventive potential against colorectal cancer. Our aim was to examine this association through a meta-analysis of observational studies. Methods: A comprehensive search for relevant articles published up to October 2012 was performed, reviews of each study were conducted and data were abstracted. Prior to meta-analysis, the studies were evaluated for publication bias and heterogeneity. Pooled relative risk (RR) estimates and 95% confidence intervals (CIs) were calculated using the random effects and the fixed effects models. Subgroup and sensitivity analyses were also performed. Results: Eight large population-based epidemiological studies (one case-control, two nested case-control analyses within a cohort and five cohort studies), involving more than 630000 participants, contributed to the analysis. We found no evidence of publication bias. However, significant heterogeneity was detected among the cohort studies. The analysis revealed a significant protective association between bisphosphonate use and colorectal cancer risk (fixed RR = 0.85, 95% CI 0.80, 0.90, random RR = 0.85, 95% CI 0.75, 0.96). When the analysis was stratified into subgroups according to study design, the association was inverse in both case-control and cohort studies, but only in the former was it statistically significant. The sensitivity analysis confirmed the stability of our results. Furthermore, we found evidence for a dose effect; Long term bisphosphonate use was associated with a 27% decrease in the risk of developing colorectal cancer as compared with non-use (RR = 0.73, 95% CI 0.57, 0.93). Conclusion: Our findings support a protective effect of bisphosphonates against colorectal cancer. However, further evidence is warranted. © 2013 The British Pharmacological Society.en
dc.language.isoengen
dc.sourceBritish journal of clinical pharmacologyen
dc.subjectPublishingen
dc.subjectArticleen
dc.subjectMeta-analysisen
dc.subjectHumanen
dc.subjectHumansen
dc.subjectPriority journalen
dc.subjectTime factorsen
dc.subjectDose-response relationshipen
dc.subjectDrugen
dc.subjectSystematic reviewen
dc.subjectBisphosphonic acid derivativeen
dc.subjectMeta analysisen
dc.subjectCancer risken
dc.subjectPamidronic aciden
dc.subjectColorectal canceren
dc.subjectColorectal neoplasmsen
dc.subjectRisk factoren
dc.subjectAlendronic aciden
dc.subjectAnticarcinogenic agentsen
dc.subjectBisphosphonatesen
dc.subjectClodronic aciden
dc.subjectDatabasesen
dc.subjectDiphosphonatesen
dc.subjectEtidronic aciden
dc.subjectFactualen
dc.subjectIbandronic aciden
dc.subjectMedlineen
dc.subjectObservational studyen
dc.subjectRisedronic aciden
dc.subjectRisken
dc.subjectZoledronic aciden
dc.titleBisphosphonate use and risk of colorectal cancer: A systematic review and meta-analysisen
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1111/bcp.12135
dc.description.volume76
dc.description.issue3
dc.description.startingpage329
dc.description.endingpage337
dc.author.facultyΙατρική Σχολή / Medical School
dc.author.departmentΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen
dc.contributor.orcidNikolopoulos, Georgios K.[0000-0002-3307-0246]
dc.contributor.orcidBagos, Pantelis G. [0000-0003-4935-2325]
dc.contributor.orcidBonovas, Stefanos [0000-0001-6102-6579]
dc.gnosis.orcid0000-0002-3307-0246
dc.gnosis.orcid0000-0003-4935-2325
dc.gnosis.orcid0000-0001-6102-6579


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record